Helen Louise Collins sold $293K of Enliven Therapeutics, Inc. (ELVN) stock

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares of ELVN stock worth $293K, per an SEC Form 4 filed Aug 19, 2026.

The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.

The trade happened on Aug 17, 2026, 2 days before it was made public.

ELVN has moved -17.9% since the trade date, from $59.53 to $48.87 (Sep 21, 2026 close).